187 related articles for article (PubMed ID: 32853381)
21. Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism.
Douros A; Filliter C; Azoulay L; Tagalakis V
Thromb Res; 2021 Jun; 202():128-133. PubMed ID: 33836492
[TBL] [Abstract][Full Text] [Related]
22. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
Chai-Adisaksopha C; Iorio A; Crowther MA; de Miguel J; Salgado E; Zdraveska M; Fernández-Capitán C; Nieto JA; Barillari G; Bertoletti L; Monreal M;
Am J Med; 2018 Apr; 131(4):430-437. PubMed ID: 29274307
[TBL] [Abstract][Full Text] [Related]
23. An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis.
Cosmi B
Expert Opin Pharmacother; 2021 Apr; 22(5):583-594. PubMed ID: 33243038
[No Abstract] [Full Text] [Related]
24. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
25. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.
Streiff M; Milentijevic D; McCrae KR; Laliberté F; Lejeune D; Lefebvre P; Schein J; Khorana AA
J Med Econ; 2019 Nov; 22(11):1134-1140. PubMed ID: 31106638
[No Abstract] [Full Text] [Related]
26. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A; Sala Tenna A; Stewart M
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002001. PubMed ID: 28737834
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study.
Cohen AT; Wallenhorst C; Rivera M; Ay C; Schaefer B; Abdelgawwad K; Psaroudakis G; Brobert G; Ekbom A; Lee AYY; Khorana AA; Becattini C; Carrier M; Coleman CI; Martinez C
Thromb Haemost; 2024 Apr; ():. PubMed ID: 38301711
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism.
Song Y; Yang D; Hou D; She J; Song Y
Thromb J; 2023 Feb; 21(1):16. PubMed ID: 36732741
[TBL] [Abstract][Full Text] [Related]
29. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Castellucci LA; Cameron C; Le Gal G; Rodger MA; Coyle D; Wells PS; Clifford T; Gandara E; Wells G; Carrier M
JAMA; 2014 Sep; 312(11):1122-35. PubMed ID: 25226478
[TBL] [Abstract][Full Text] [Related]
30. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism.
Recio-Boiles A; Veeravelli S; Vondrak J; Babiker HM; Scott AJ; Shroff RT; Patel H; Elquza E; McBride A
World J Gastrointest Oncol; 2019 Oct; 11(10):866-876. PubMed ID: 31662825
[TBL] [Abstract][Full Text] [Related]
32. Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism.
Masini M; Toma M; Spallarossa P; Porto I; Ameri P
Curr Oncol Rep; 2023 Sep; 25(9):979-987. PubMed ID: 37278934
[TBL] [Abstract][Full Text] [Related]
33. The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis.
Mohamed MFH; ElShafei MN; Ahmed MB; Abdalla LO; Ahmed I; Elzouki AN; Danjuma MI
Clin Appl Thromb Hemost; 2021; 27():1076029620940046. PubMed ID: 33651658
[TBL] [Abstract][Full Text] [Related]
34. Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs.
Schaefer JK; Li M; Wu Z; Basu T; Dorsch MP; Barnes GD; Carrier M; Griggs JJ; Sood SL
J Thromb Haemost; 2021 Jan; 19(1):212-220. PubMed ID: 33104289
[TBL] [Abstract][Full Text] [Related]
35. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
[TBL] [Abstract][Full Text] [Related]
37. Anticoagulation therapy in cancer associated thromboembolism - new studies, new guidelines.
Hirmerová J
Vnitr Lek; 2020; 66(4):225-231. PubMed ID: 32972179
[TBL] [Abstract][Full Text] [Related]
38. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Akl EA; Labedi N; Barba M; Terrenato I; Sperati F; Muti P; Schünemann H
Cochrane Database Syst Rev; 2011 Jun; (6):CD006650. PubMed ID: 21678361
[TBL] [Abstract][Full Text] [Related]
39. Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis.
Martinez BK; Sheth J; Patel N; Baker WL; Coleman CI
Pharmacotherapy; 2018 Jun; 38(6):610-618. PubMed ID: 29604102
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
Dawwas GK; Brown J; Dietrich E; Park H
Lancet Haematol; 2019 Jan; 6(1):e20-e28. PubMed ID: 30558988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]